TELO Telomir Pharmaceuticals, Inc.

Fundamentals / CIK 0001971532 / USD

Telomir Pharmaceuticals, Inc. reported $4.64M in total assets and a net loss of $5.48M through December 31, 2025 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open TELO in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

4 fiscal years (2022 to 2025), reported in USD.

$0$0$0-$15.46MFY 2022 Net Income: -$854K2022FY 2023 Net Income: -$13.07M2023FY 2024 Net Income: -$16.53M2024FY 2025 Net Income: -$10.41M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31 Dec 31
Research & Development $2.44M $2.24M $1.57M $833K
Total Operating Expenses $10.54M $12.24M $3.94M $854K
Interest Income $126K $48K -- --
Interest Expense -- $4.34M $1.64M --
Net Income -$10.41M -$16.53M -$13.07M -$854K
Basic EPS -$0.33 -$0.56 $0.48 -$0.03
Diluted EPS -$0.33 -$0.56 $0.48 -$0.03
Basic Shares Outstanding 31.7M 29.5M 27.3M 26.8M
Diluted Shares Outstanding 31.7M 29.5M 27.3M 26.8M

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Research & Development $252K $445K $468K $1.30M $760K $43K $337K $269K
Total Operating Expenses $745K $1.76M $1.04M $2.13M $1.15M $5.07M $2.19M $2.91M
Operating Income -- -- -- -- -- -- $2.19M --
Interest Income $42K $46K $52K $72K $44K $1.4K $8.0K --
Interest Expense $1.9K $3.0K $1.3K -- $0 $1.3K $46 --
Net Income -$705K -$1.72M -$991K -$2.06M -$1.10M -$5.07M -$2.18M -$2.90M
Basic EPS -$0.01 -$0.79 -$0.03 -- -$0.03 -$0.17 -$0.07 --
Diluted EPS -$0.01 -$0.79 -$0.03 -- -$0.03 -$0.17 -$0.07 --
Basic Shares Outstanding 68.8M 60.8M 34.4M -- 32.4M 30.0M 29.8M --
Diluted Shares Outstanding 68.8M 60.8M 34.4M -- 32.4M 30.0M 29.8M --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $7.29M $1.27M $1.2K $1.4K
Cash & Short-Term Investments $7.29M $1.27M $1.2K $1.4K
Total Current Assets $7.34M $1.32M $435K $49K
Total Non-Current Assets $0 $0 $4.34M $0
Total Assets $7.34M $1.32M $4.77M $49K
Accounts Payable -- -- $475K --
Other Current Liabilities $318K $93K $527K --
Total Current Liabilities $1.43M $681K $1.34M $986K
Total Non-Current Liabilities $0 $0 $0 $0
Total Liabilities $1.43M $681K $1.34M $986K
Retained Earnings -$41.01M -$30.60M -$14.06M -$992K
Total Stockholders' Equity $5.91M $643K $3.44M -$937K
Total Equity $5.91M $643K $3.44M -$937K

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Cash & Cash Equivalents $4.52M $5.17M $5.56M $7.29M $7.33M $754K $403K $1.27M
Cash & Short-Term Investments $4.52M $5.17M $5.56M $7.29M $7.33M $754K $403K $1.27M
Total Current Assets $4.64M $5.37M $5.79M $7.34M $7.40M $830K $491K $1.32M
Total Non-Current Assets $0 $0 $0 $0 $0 $0 $0 $0
Total Assets $4.64M $5.37M $5.79M $7.34M $7.40M $830K $491K $1.32M
Other Current Liabilities -- -- $345K $318K $93K $93K $93K $93K
Total Current Liabilities $237K $332K $827K $1.43M $423K $348K $652K $681K
Total Non-Current Liabilities $0 $0 $0 $0 $0 $0 $0 $0
Total Liabilities $237K $332K $827K $1.43M $423K $348K $652K $681K
Retained Earnings -$44.43M -$43.72M -$42.00M -$41.01M -$38.95M -$37.85M -$32.78M -$30.60M
Total Stockholders' Equity $4.40M $5.03M $4.96M $5.91M $6.98M $481K -$161K $643K
Total Equity $4.40M $5.03M $4.96M $5.91M $6.98M $481K -$161K $643K

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31 Dec 31
Net Income -$10.41M -$16.53M -$13.07M -$854K
Stock-Based Compensation $5.29M $6.87M -- --
Operating Cash Flow -$3.69M -$5.07M -$3.86M -$469K
Common Stock Issued $9.60M $6.83M $1.00M --
Financing Cash Flow $9.71M $6.34M $3.86M $470K
Net Change in Cash $6.02M $1.26M -$188 $1.4K

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Net Income -$705K -$1.72M -$991K -$2.06M -$1.10M -$5.07M -$2.18M -$2.90M
Stock-Based Compensation $65K $199K $40K -$7.9K -$742K $4.66M $1.38M --
Operating Cash Flow -$586K -$1.01M -$1.77M -$1.20M -$927K -$696K -$863K -$606K
Common Stock Issued -- -- -- -- -- -- -- $1.00M
Financing Cash Flow -$68K $622K $47K -- -- -- -- $1.04M
Net Change in Cash -$655K -$390K -$1.73M -$43K $6.57M $351K -$863K $431K

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31 Dec 31
Return on Equity (ROE) -176.1% -2571.0% -380.2% --
Return on Assets (ROA) -141.8% -1248.7% -273.8% -1752.8%
Current Ratio 5.14x 1.94x 0.33x 0.05x
Quick Ratio 5.10x 1.86x 0.00x 0.00x
EPS Growth (YoY) -- -216.7% -- --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Return on Equity (ROE) -124.4% -116.7% -185.9% -176.1% -161.2% -3353.7% -- -2571.0%
Return on Assets (ROA) -118.0% -109.5% -159.3% -141.8% -152.0% -1945.3% -2536.3% -1248.7%
Current Ratio 19.60x 16.14x 7.00x 5.14x 17.51x 2.38x 0.75x 1.94x
Quick Ratio 19.07x 15.55x 6.72x 5.10x 17.33x 2.17x 0.62x 1.86x
Operating Income Growth (YoY) -- -- -- -- -- -- +14.2% --
EPS Growth (YoY) -- -- -- -- -- -440.0% -- --
Source: SEC EDGAR CompanyFacts (CIK 0001971532) · from December 31, 2022 Data through September 30, 2026 · synced Nov 21, 2026, 05:00 UTC · Open in terminal